Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
WEST LAFAYETTE, March 05, 2018 -- Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment , today announced that the company’s management team will present at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12th at 2:50 p.m. EDT.
A live audio webcast of the Company's presentation can be accessed by visiting "Events & Presentations" under the Investors & News section of Endocyte's website at www.endocyte.com. The webcast will be archived shortly after the live event, and a replay will be available on the Company's website for 90 days following the conference.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering Phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR-T therapy into the clinic in 2018, where it will be studied in osteosarcoma. For additional information, please visit Endocyte's website at www.endocyte.com.
Investor Contact:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
